Alpine Immune Sciences a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Co.'s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Co.'s autoimmune/inflammatory diseases products include: ALPN-101, which is a dual inducible T cell costimulator and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases; and ALPN-303, which is a dual B cell cytokine antagonist being developed for B cell-mediated autoimmune/inflammatory diseases. The ALPN stock yearly return is shown above.
The yearly return on the ALPN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ALPN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|